查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496011

全球胰島素輸送設備市場 - 2024 年至 2029 年預測

Global Insulin Delivery Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

胰島素輸送設備市場預計將從 2022 年的 134.71 億美元增加到 2029 年的 205.31 億美元，複合年成長率為 6.21%。

受技術進步、對患者的強烈關注以及糖尿病治療進步的影響，胰島素輸送設備市場持續成長。市場的擴張與糖尿病盛行率的不斷上升以及胰島素發行策略和方法的進步有關。

致命性糖尿病在全球範圍內日益佔據主導地位，加上依賴胰島素治療的兒童糖尿病發病率不斷上升，預計未來幾年該市場將擴大。據世界衛生組織(WHO)稱，糖尿病是約150萬人死亡的直接原因，其中48%的糖尿病死亡發生在70歲以下的人群中。此外，2019年全球約20%的心血管疾病是由血糖值升高引起的。

此外，根據2021年12月美國國家醫學圖書館的一篇論文，2019年兒童第1型糖尿病的標準化發生率為每10萬人中24.7人，到2030年也將達到每10萬人中24.7人，預計這一數字將增加至34.8人。 1 型糖尿病患者數量的增加預計將增加對胰島素的需求，進而擴大全球胰島素輸送設備的市場規模。缺乏胰島素，加上技術開拓和負擔得起的產品供應，預計將在預測期內顯著促進胰島素輸送設備市場的成長。

市場促進因素：

  • 糖尿病人口的增加預計將推動全球對胰島素輸送設備的需求。

由於多種原因，特別是穩定的生活方式、不良飲食和肥胖，全世界糖尿病的盛行率正在增加。這將導致胰島素治療和輸送設備需求的增加。智慧胰島素筆和貼片幫浦等創新進步使胰島素注射變得更容易，對糖尿病患者也更有吸引力。強調以患者為中心的護理將有助於這些設備的選擇，促進和提高生活品質，減少注射負擔，並提高治療依從性。

此外，2021年11月，國際糖尿病聯盟發布的報告指出，全球約有5.37億人患有糖尿病，比2019年的數字增加了16%。報告也估計，中國和印度等人口大國的糖尿病患者人數最多，成年人口分別約 1.41 億和 7,400 萬人。

此外，根據 IDF 的數據，印度約 53.1% 的糖尿病患者患有未確診的糖尿病，另有 4,000 萬人患有葡萄糖耐受不良(IGT)。這增加了罹患第 2 型糖尿病的風險，增加了對胰島素的需求，並開拓了胰島素輸送設備的市場。

根據 2021 年世衛組織全球糖尿病契約報告，低收入和中等收入國家中 50% 的第 2 型糖尿病患者無法獲得胰島素，而需要在 39% 的醫療機構中使用人類胰島素。預計這些方面將透過在所需國家提供胰島素設備來提高市場參與者的滲透率。

  • 不斷進步的技術可能會增強對胰島素輸送設備的需求。

科技的進步正在推動對先進胰島素輸送設備的需求。其中包括智慧胰島素筆、連接的連續血糖監測系統、閉合迴路的貼片幫浦幫浦、無針噴射注射器、植入式幫浦、人工胰臟系統、雙腔室設備、生物相容性材料、先進的輸液器和資料整合、雲端連接、可自訂的劑量演算法等等。這些進步提高了胰島素給藥的有效性、便利性和使用者體驗。

此外，資訊來源稱，160 萬美國人患有第 1 型糖尿病，該地區每天診斷出 100 多例病例。預計在預測期內，對抗第 1 型糖尿病和促進胰島素使用的技術開拓將為市場參與者提供利潤豐厚的市場機會。

主要進展

  • 2023年6月－諾和諾德與BIO JAG談判收購BIOCORP股份（佔股本45.3%，理論投票權62.2%）。收購完成後，將對所有剩餘的 BIOCORP 證券進行簡短要約收購，如果滿足法律要求，將強制擠出剩餘股東並使 BIOCORP 退市。 BIOCORP 是一家法國公司，專注於輸送系統和創新醫療設備，包括用於筆式注射器的藍牙智慧附加元件設備 Mallya。
  • 2023 年 2 月 - 禮來公司宣布將以低成本向國際機構（孟加拉）有限公司（IABL）供應人類胰島素 API。 (IABL) 宣布將以更低的價格供應人類胰島素原料藥，以提高到 2030 年孟加拉約 100 萬名糖尿病患者的負擔能力和可及性。 IABL 計畫到 2025 年，根據世界衛生組織 (WHO) 全球糖尿病契約，專用孟加拉國市場生產和完成自有品牌的人類胰島素管瓶和藥筒。
  • 2022 年 11 月 -Medtronic)開發了一種系統，可以使患者佩戴胰島素泵輸液器的時間增加一倍，由於瘙癢和瘀傷等問題，患者通常每兩到三天更換一次胰島素泵輸液器。此系統使用的材料可減少胰島素防腐劑流失並保持藥物流動和穩定性。該系統在臨床試驗中得到檢驗，第 7 天結束時的存活率為 77.8%。
  • 2022 年 4 月 - Insulet 的 Omnipod 5 獲得 FDA 批准，這是首款適用於 6 歲及以上 1 型糖尿病患者的無管、穿戴式、自動化胰島素輸送系統。該系統使用 Dexcom 的 G6 連續血糖監測 (CGM) 系統來提供更輕鬆的血糖管理，而無需使用每日多次注射、試管和指尖採血。患者可以使用手持控制器或安全的智慧型手機應用程式控制系統。臨床研究表明，範圍時間得到改善，糖化血紅蛋白水平降低。 Omnipod 5 每 5 分鐘發送一次 Dexcom CGM 值，並預測接下來 60 分鐘的血糖值。

提供的產品

  • 諾和諾德 (Novo Nordisk) A/S 的 NovoPen(R) 4 - NovoPen(R) 4 是一款易於使用的胰島素泵，具有堅固的設計，可確保準確無憂的劑量，以及可在需要時可輕鬆更換，並發出喀喀聲。劑量選項是 3 毫升筆筒，最多可輸送 60 單位的胰島素。
  • T:slimX2 胰島素幫浦 - T:slimX2 胰島素幫浦是 Tandem 的產品，是一種先進的現代設備，最多可容納 300 單位的胰島素。它具有彩色觸控螢幕、個人化設定、可充電電池和斷開連接功能。透過與相容的 CGM 感測器配對，您可以實現自動胰島素給藥系統。 Control-IQ 技術根據感測器讀數提前 30 分鐘預測血糖水平，並根據需要自動調整胰島素，使糖尿病管理變得更加容易。

主要市場區隔

胰島素輸送設備市場細分與分析如下：

按類型

  • 注射器
  • 胰島素幫浦
  • 吸入器
  • 其他

按用途

  • 一型糖尿病
  • II型糖尿病
  • 妊娠糖尿病

按最終用戶

  • 醫院和診所
  • 門診護理中心
  • 居家照護環境

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
  • 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 日本
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章胰島素輸送設備的全球市場：按類型

  • 介紹
  • 注射器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 胰島素幫浦
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 吸入器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球胰島素輸送設備市場：依應用分類

  • 介紹
  • 1型糖尿病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 2型糖尿病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 妊娠糖尿病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章胰島素輸送設備的全球市場：依最終用戶分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診治療中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 居家照護設置
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球胰島素輸送設備市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 有競爭力的儀表板

第10章 公司簡介

  • Novo Nordisk A/S
  • Beckton, Dickinson and Company
  • Medtronic
  • Sanofi
  • Eli Lilly and Company
  • Ypsomed AG
  • Biocon Limited
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • F. Hoffman-La Roche Ltd.
簡介目錄
Product Code: KSI061612023

The global insulin delivery devices market is estimated to witness a compound annual growth rate of 6.21% and reach US$20.531 billion by 2029, up from US$13.471 billion in 2022.

The market of insulin delivery devices is continuously rising with the impact of advances in technology, persistent patient inclinations, and the advancing diabetes care aspects. The market's expansion is connected to the expanding prevalence of diabetes and endeavors to progress insulin delivery strategies and methods.

The rising predominance of diabetes resulting in fatalities all over the world, coupled with expanding occurrences of childhood diabetes subordinate to insulin for care, is expected to move the market extension within the years ahead. As per the World Health Organization (WHO), diabetes was the straightforward cause of about 1.5 million deaths, and 48% of deaths coming from diabetes happened before the age of 70. Furthermore, raised blood glucose caused around 20% of cardiovascular illnesses around the world in 2019.

Furthermore, as per the National Library of Medicine article of December 2021, the standardized incidence of type 1 diabetes in children was 24.7 per 100,000 in 2019, which is also expected to rise to 34.8 per 100,000 PY in 2030. This rise in the number of type-1 diabetes individuals is predicted to boost the requirement for insulin, which in turn expands the market size of insulin delivery devices globally. Technological developments coupled with affordable product availability along with lack of access to insulin are together anticipated to push the market growth for insulin delivery devices at a significant scale during the forecast period.

Market Drivers:

  • The growing diabetic population is expected to boost the demand for insulin delivery devices globally.

The predominance of global diabetes is increasing because of various causes specifically, due to stationary lifestyles, poor diet, and obesity. This will lead to a rising request for demand in insulin treatment and delivery devices. Innovative advancements like smart insulin pens and patch pumps make administrating of insulin more user-friendly and engaging to diabetic patients. The accentuation on patient-centric care is driving the selection of these devices, promoting and providing a progressed quality of life, decreased injection burden, and improved treatment adherence.

Additionally, in November 2021 a report was released by the International Diabetes Federation that stated about 537 million individuals are living with diabetes around the world, which is an increment of 16% from the 2019 numbers. The sources also inferred that populated nations such as China and India have the most noteworthy number of diabetic individuals, with an adult population of about 141 million and 74 million within the nation.

Besides, as per the IDF, around 53.1% of the diabetic Indian populace is undiscovered for diabetes, with an extra 40 million individuals living with impaired glucose tolerance (IGT). This could cause a higher risk of developing type 2 diabetes, in this manner expanding the demand for insulin, coming about within the market expansion of insulin delivery devices as well.

As per the 2021 WHO Global Diabetes Compact Report, there's a absence of insulin accessibility to 50% of the individuals with type 2 diabetes, and a need of human insulin in 39% of the healthcare facilities in low- and middle-income nations. Aspects such as these are projected to offer market players increased penetration by offering insulin devices in the needed countries.

  • Rising technological advancement would bolster the demand for insulin delivery devices.

Technological advancements are driving the demand for advanced insulin delivery devices. These include smart insulin pens, connected continuous glucose monitoring systems, patch pumps with closed-loop systems, needle-free jet injectors, implantable pumps, artificial pancreas systems, dual-chamber devices, biocompatible materials, advanced infusion sets, data integration, cloud connectivity, and customizable dosing algorithms. These advancements enhance the effectiveness, convenience, and user experience of insulin administration.

Additionally, as per the source, 1.6 million Americans live with Type 1 diabetes, and more than 100 cases are diagnosed daily in the region. The development of technologies for battling type-1 diabetes and promoting insulin use is projected to offer the market players profitable market opportunities in the forecasted period.

Key Developments:

  • June 2023- Novo Nordisk negotiated with BIO JAG to acquire its entire stake in BIOCORP, which represents 45.3% of its share capital and 62.2% of its theoretical voting rights. The acquisition followed by a simplified tender offer on all remaining outstanding BIOCORP securities, and if legal requirements are met, a mandatory squeeze-out of remaining shareholders and delisting of BIOCORP. BIOCORP is a French company specializing in delivery systems and innovative medical devices, including the Bluetooth-enabled smart add-on device for pen injectors, Mallya.
  • February 2023- Eli Lilly and Company stated the supply of its API for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) to improve affordability and access for nearly one million people with diabetes in Bangladesh by 2030. IABL plans to manufacture and finish human insulin vials and cartridges under its own brand name by 2025, exclusively for the Bangladesh market, in line with the World Health Organization's Global Diabetes Compact.
  • November 2022- Medtronic developed a system to double the wear time of insulin pump infusion sets, which patients typically change every two to three days due to issues like itching and bruising. The system uses materials to reduce the loss of insulin preservatives and maintain drug flow and stability. The system was validated in clinical trials, with a survival rate of 77.8% at the end of day seven. The company believes the extended-wear system can reduce cost and plastic waste, with users changing their devices 75 fewer times, resulting in annual savings of over $1,000.
  • April 2022- Insulet received FDA clearance for its Omnipod 5, the first tubeless, wearable, automated insulin delivery system for individuals aged six and older with type 1 diabetes. The system uses Dexcom's G6 continuous glucose monitoring (CGM) system and offers easier glucose management without multiple daily injections, tubes, or fingersticks. Patients can control the system with a handheld controller or a secure smartphone app. Improved time in range and lower levels of glycosylated hemoglobin were seen in a clinical investigation. Every five minutes, the Omnipod 5 transmits a Dexcom CGM value and forecasts the glucose levels for the next sixty minutes.

Product Offered:

  • NovoPen(R) 4- NovoPen(R) 4 from Novo Nordisk A/S is a user-friendly insulin pump with a robust design that ensures accurate and reassuring dose delivery and features an audible end-of-dose click for ease of use and change when needed. The dosing option is a 3ml pen fill cartridge that can deliver up to 60 units of insulin at a maximum dose. Its robust design lasts up to 5 years.
  • T:slim X2 insulin pump- The t:slim X2 insulin pump is a product from Tandem, it is a sophisticated, modern device that can hold up to 300 units of insulin. It features a color touchscreen, personalized settings, a rechargeable battery, and the ability to disconnect. It can pair with a compatible CGM sensor for an automated insulin delivery system. Control-IQ technology uses sensor values to predict glucose levels 30 minutes ahead and automatically adjust insulin if needed, making diabetes management easier.

Key Market Segmentation:

Global Insulin Delivery Devices Market is segmented and analyzed as below:

By Type

  • Syringes
  • Insulin Pumps
  • Inhalers
  • Others

By Application

  • Type I Diabetes
  • Type II Diabetes
  • Gestational Diabetes

By End-Users

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Home Care Settings

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Other

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL INSULIN DELIVERY DEVICES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Syringes
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Insulin Pumps
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Inhalers
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL INSULIN DELIVERY DEVICES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Type I Diabetes
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Type II Diabetes
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Gestational Diabetes
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL INSULIN DELIVERY DEVICES MARKET BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Home Care Settings
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL INSULIN DELIVERY DEVICES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End-Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End-Users
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End-Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End-Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Novo Nordisk A/S
  • 10.2. Beckton, Dickinson and Company
  • 10.3. Medtronic
  • 10.4. Sanofi
  • 10.5. Eli Lilly and Company
  • 10.6. Ypsomed AG
  • 10.7. Biocon Limited
  • 10.8. Insulet Corporation
  • 10.9. Tandem Diabetes Care, Inc.
  • 10.10. F. Hoffman-La Roche Ltd.